• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CEO CORNER
    • SCIENTIFIC ADVISORY BOARD
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • ANALYST COVERAGE
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Press Release

Akari TX / February 11, 2026

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC …

[Read more...] about Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

Akari TX / February 5, 2026

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Live video webcast on Tuesday, February 10th at 1:00 PM EST TAMPA and LONDON – February 5, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology …

[Read more...] about Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Akari TX / January 26, 2026

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 …

[Read more...] about Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Akari TX / January 9, 2026

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Access the Akari CEO Corner here TAMPA, FL and LONDON – January 9, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …

[Read more...] about Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Akari TX / January 8, 2026

Akari Therapeutics to Present at the 2026 Biotech Showcase

In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, …

[Read more...] about Akari Therapeutics to Present at the 2026 Biotech Showcase

Next Page »

Footer

FOLLOW US

X
LINKEDIN
Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.